Weight Management Therapeutic Platform
Zorqalyx has completed Phase 4 trials and remains on track for August 2026 availability.
A once-weekly metabolic modulation therapy engineered for sustained weight reduction, physician supervision workflows, and structured long-term adherence support.
Clinical evidence profile
Zorqalyx Phase 4 outcomes showed durable weight-loss maintenance and improved metabolic marker consistency when combined with supervised lifestyle protocols.
Expanded population confidence
Phase 4 included diverse demographic and comorbidity cohorts to assess real-world resilience.
Longitudinal endpoint retention
Observed durable efficacy and adherence signals over extended monitoring intervals.
Integrated care compatibility
Structured for use alongside physician-led nutrition, activity, and follow-up care plans.
Safety and supervision
Zorqalyx is intended for prescription use and should be managed under clinician supervision. Individual suitability, contraindications, and monitoring requirements must be evaluated by a licensed medical professional.
This page is not medical advice, diagnosis, or treatment guidance.
Availability timeline
-
Q1 2026
Regulatory package finalization and manufacturing scale-readiness checkpoints.
-
Q2 2026
Distribution partner onboarding and clinical education rollout.
-
August 2026
Planned initial market availability, pending final regulatory and supply confirmations.